606101-79-5

Usage

Molecular structure

The compound has a 1H-indeno[5,4-f]quinoline core, which is a fused ring system consisting of a quinoline ring and an indene ring.

Fluoro substituent

The molecule contains a 3-fluoro substituent, which is attached to the carboxylic acid side chain.

Carboxylic acid side chain

The compound has a carboxylic acid group (-COOH) attached to the core structure, which may contribute to its potential applications in medicinal chemistry.

Multiple methyl groups

The molecule has 14 hydrogen atoms replaced with methyl groups (-CH3), which are distributed across the fused ring system.

Stereochemistry

The compound's stereochemistry is specified as (4aS,4bS,6aS,7S,9aS,9bS,11aR), indicating the spatial arrangement of the atoms and the chirality of the molecule.

Tetradecahydro

The compound is tetradecahydro, meaning it contains 14 hydrogen atoms within its structure, which may affect its physical and chemical properties.

Potential applications

Due to its unique structural features, 1H-Indeno[5,4-f]quinoline-7-carboxylic acid, 3-fluoro-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1,4a,6a-triMethyl-2-oxo-, (4aS,4bS,6aS,7S,9aS,9bS,11aR)- may have potential applications in medicinal chemistry and pharmaceutical research, such as the development of new drugs or the study of molecular interactions.

Complexity

The compound is highly complex due to its fused ring system, multiple substituents, and stereochemistry, which may make it challenging to synthesize and study.

Upstream product

• 606101-78-4 2-Fluoro-4-methyl-3-oxo-4-aza-5α-androst-1-ene-17β-carboxylic acid methyl ester 
• 86283-81-0 methyl-3-oxo-4-methyl-4-aza-5α-androstane-17β-carboxylate 
• 103335-41-7 methyl 3-oxo-4-aza-5α-androst-1-ene-17β-carboxylate 
• 606101-77-3 2α-Fluoro-4-methyl-3-oxo-4-aza-5α-androstane-17β-carboxylic acid methyl ester 

Downstream Products

• 606101-58-0 MK-0773 
• 606101-58-0 C₂₇H₃₄FN₅O₂ 

Relevant academic research and scientific papers

Salt of an androgen receptor modulator

The biphthalate salts of compound I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can

Polymorphs of an androgen receptor modulator

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can b

Process for making fluorinated 4-azasteroid derivatives

The present invention relates to synthetic processes useful in the preparation of fluorinated 4-azasteroid derivatives that modulate androgen receptors and have application in the treatment of conditions caused by androgen deficiency or androgen receptor hyperactivity, such as osteoporosis, periodontal disease, bone fracture, frailty, erectile dysfunction, loss of libido, androgen-dependent cancers and sarcopenia. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.

FLUORINATED 4-AZASTEROIDS AS ANDROGEN RECEPTOR MODULATORS

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can b

17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or i

17-HETEROCYCLIC-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS

Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, benign prostatic hyperplasia (BPH), abdominal adiposity, metabolic syndrome, type II diabetes, cancer cachexia, Alzheimer’s disease, muscular dystrophies, cognitive decline, sexual dysfunction, sleep apnea, depression, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.